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Abstract
Giant Cell Glioblastoma (gcGBM) and Pleomorphic Xanthoastrocytoma (PXA) are rare
astroglial tumors of the central nervous system. Although they share certain histomorpholo-
gical and immunohistochemical features, they are characterized by different clinical behav-
ior and prognosis. Nevertheless, few cases remain uncertain, as their histomorphological
hallmarks and immunophenotypes do correspond to the typical pattern neither of gcGBM
nor PXA. Therefore, in addition to the routinely used diagnostic histochemical and immuno-
histochemical markers like Gömöri, p53 and CD34, we analyzed if genetic variations like
MGMT promoter methylation, mutations in the IDH1/2 genes, or BRAFmutations, which are
actually used as diagnostic, prognostic and predictive molecular markers in anaplastic glial
tumors, could be helpful in the differential diagnostic of both tumor entities. We analyzed 34
gcGBM and 20 PXA for genetic variations in the above-named genes and found distinct dis-
tributions between both groups.MGMT promoter hypermethylation was observed in 3 out
of 20 PXA compared to 14 out of 34 gcGBM (15% vs. 41.2%, p-value 0.09). BRAF V600E
mutations were detected in 50% of the PXA but not in any of the gcGBM (50% vs. 0%, p-
value < 0.001). IDH1 R132 and IDH R172 mutations were not present in any of the PXA and
gcGBM cases. Our data indicate, that in addition to the histological and immunohistochemi-
cal evaluation, investigation ofMGMT promoter methylation and in particular BRAF V600E
mutations represent reliable additional tools to sustain differentiation of gcGBM from PXA
on a molecular basis. Based on these data specific BRAF kinase inhibitors could represent
a promising agent in the therapy of PXA and their use should be emphasized.
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Introduction
Giant Cell Glioblastoma (gcGBM) and Pleomorphic Xanthoastrocytoma (PXA) are rare astro-
cytic neoplasms of the CNS, both with an equivalent incidence of<1% of all brain tumors[1,2].
gcGBM correspond to WHO grade IV tumors with a one-year-survival rate of less than 50%
[2]. With 5 years recurrence-free survival rates of 72% PXA have a much better prognosis and
therefore are classified as WHO grade II tumors[3]. In cases with high mitotic activity (5 or
more mitoses per 10 HPF (high power fields)) and/or necrosis, the designation “PXA with ana-
plastic features” (PXA-A) is used[1,3]. Age distribution of gcGBM varies among adults between
45 and 75 years compared to PXA that occur predominantly in children and young adults[1,2].
The development of gcGBM is “de novo” and highly related to mutations of the TP53 gene[2],
whereas TP53mutations are rather uncommon in PXA[4–9].
Histologically, gcGBM and PXA share several features, which sometimes turns simple histo-
morphological differentiation into a difficult task[8]. In particular, the pleomorphic appear-
ance combined with the presence of mono- or multinucleated giant astroglial tumor cells is a
common histological feature, which aggravates the differentiation of both tumors. Reticulin
fiber depositions are more characteristic for PXA but can also be present in gcGBM. Both
tumors express, consistent with their glial lineage, the glial fibrillary acidic protein (GFAP),
whereas other markers are reported to have distinct immunoreactivity, e.g. the endothelial
marker CD34 is frequently expressed in tumor cells of PXA, respectively not in tumor cells of
gcGBM[10]. Furthermore, nuclear p53 accumulation is typical for gcGBM, but not expected to
be found in equal amounts in PXA[10]. Nevertheless, some cases demand additional diagnostic
markers due to their untypical immunophenotype.
Detection of molecular alterations, including O6-methylguanine DNA methyltransferase
(MGMT) promoter methylation, isocitrate dehydrogenase-1 and -2 (IDH1/2)mutations and B-
rapidly accelerated fibrosarcoma (BRAF) V600E mutations, are state of the art in the diagnostic
management of gliomas as they are highly associated with histologically defined glioma sub-
types, have predictive relevance (MGMT status in malignant glioma in patients older than 60
years) and define molecular glioma subtypes (IDH1/2mutated gliomas), all representing sub-
stantial values for therapeutic and clinical outcome[11–14].MGMT promoter methylation
occurs in 40% of primary glioblastoma and is associated with an increased survival after radio-
therapy and chemotherapy with temozolomide[15,16]. Further molecular phenomena, which
have diagnostic and prognostic relevance, are mutations in the IDH1 gene and its mitochon-
drial isoform IDH2[17–19]. IDH1mutations are present in the vast majority of low-grade dif-
fuse astrocytoma[20,21], as well as in secondary glioblastoma[22,23]. Rearrangement, e.g. the
copy number gain of the BRAF gene, located on chromosome 7q34, has been reported as a
prevalent molecular alteration in pilocytic astrocytoma (WHO grade I) while being absent in
most of other glial tumors[24–26]. Other BRAF alterations, in particular the T! A transver-
sion at codon 600 with consecutive amino acid conversion from valine to glutamic acid have
recently been identified in extra-cerebellar pilocytic astrocytoma, pleomorphic xanthoastrocy-
toma and ganglioglioma[27]. Moreover, detection of BRAF (V600E) mutations have been sug-
gested to be helpful to distinguish PXA from diffuse astrocytic tumors WHO grade II, III and
IV elsewhere[28]. Mutations of the TP53 tumor suppressor gene, located on chromosome
17p13, are the most common mutations in different types of human cancer[5,6],[29,30]. In
particular, giant cell glioblastoma are characterized by high numbers of TP53mutations,
respectively 75–90% of the cases[31], whereas the frequency of TP53mutations found in PXA
is low. Therefore, the TP53mutations status might represent a reliable diagnostic marker in the
discrimination of gcGBM and PXA[4,7–9].
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The aim of this study was to analyze whether genetic changes ofMGMT, IDH1/2 and BRAF
occur in PXA or gcGBM and if these genetic changes, respectively their distinct distribution
pattern, could be used as molecular markers in the differentiation of these glial tumor entities.
Materials and Methods
Patients and tumor samples
Paraffin embedded tumor material from 20 PXA and 34 gcGBM were selected for histomor-
phological, immunohistochemical and molecular genetic analysis. Prior to DNA extraction, all
tumors were reviewed by at least two neuropathologists and histopathological diagnoses were
rendered according to the revised WHO 2007 classification criteria of CNS tumors using stan-
dard histological and immunohistochemical methods[2]. Clinical information was obtained
retrospectively from chart review or from the online medical record SAP, according to the pro-
tocols of maintenance of patient’s confidentiality. For 3 cases clinical information were not
available. All patients gave written consent at the date of surgical intervention for the use of
their tissue within these studies. The study was reviewed and approved by the local ethics com-
mittee of the Charité-University (approval number EA2/101/08).
Histological and immunohistochemical analysis
Hematoxylin-and-eosin (HE)- and reticulin staining was performed on 4 μm tissue sections from
formalin-fixed, paraffin-embedded tumor specimens and evaluated for the presence of pleomor-
phic appearance including multinucleated giant tumor cells, giant tumor cells, perivascular lym-
phocytes, angiocentric tumor cell growth, vascular proliferates, necrosis and the extent of
argyrophilic fiber networks. Moreover, calcification, hemosiderin deposition and mitotic activity
(mitoses per 10 HPF) were taken into account. Reticulin fiber networks were evaluated as “posi-
tive” when not only confined to the vessel walls but present in more than 30% of the tumor
matrix. Immunohistochemistry was carried out for the detection of GFAP (polyclonal, code
Z0334, 1:2000, Dako, Glostrup, Denmark), MAP2 (monoclonal, codeM4403, 1:10000, Sigma-
Aldrich, St. Louis, USA), p53 (monoclonal, codeM7001, 1:100, Dako, Glostrup, Denmark), CD34
(monoclonal, codeM1765, 1:100, Dako, Glostrup, Denmark) and Ki-67 (monoclonal, code
M7240, 1:100, Dako, Glostrup, Denmark), on 4 μm paraffin sections using a Ventana BenchMark
XT1 immunostainer (Ventana Medical Systems, Tucson, AZ) following the corresponding Ven-
tana staining procedure. p53 positivity was defined as strong nuclear accumulation present in
more than 30% of the tumor cells. For CD34-analysis, cytoplasmic staining of tumor cells was
scored semi-quantitatively as described elsewhere[10]. CD34-positivity was rendered to tumors
harboring more than 10% of CD34-expressing tumor cells. Evaluation of Ki-67 was performed in
tumor areas with the highest Ki-67 labeling index by counting all tumor cells in one HPF.
DNA extraction
Tumor tissues for DNA extraction for subsequentMGMT promoter methylation status, IDH1/2
and BRAFmutation analysis was extracted from formalin-fixed, paraffin-embedded tissue, e.g.
from 10 to 15 paraffin sections of 10 μm each after labeling on hematoxylin and eosin-stained
sections. Contaminating necrotic debris, hemorrhage or normal brain tissue was excluded and
only representative areas, showing an estimated tumor cell content of at least 80% have been cho-
sen for molecular analysis. For DNA extraction from paraffin material the QIAamp DNAmini
kit (Qiagen, Valencia, CA) was used. The kit was employed in accordance to the manufacturer’s
instructions. Standardized quantitative and qualitative DNA assessment was performed with the
NanoDrop ND-1000 Spectrophotometer and its corresponding software.
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PCR amplification of MGMT, IDH1/2 and BRAF
Information on the regions of interest, primer sequences and conditions for PCRs are listed in
S1 Table. Each probe contained 12,5 μl Pyromark Mastermix, 2,5 μl Coral load (both pur-
chased from Qiagen, Valencia, CA), 6 μl DNase-free water, 0,5 μl of the corresponding
sequencing primer and 3 μl of the template due to manufacturer´s manual.
MGMTmethylation analysis
For assessment of theMGMT promoter methylation status a quantitative methylation-specific
pyrosequencing technique was used, which interrogates 5 CpGs and therefore permits stan-
dardization with defined cut-off points. Cut-off points were defined in accordance to prospec-
tively validated controls and accounted for a methylation percentage of 10% of at least two
CpGs, or> 20% in one CpG. The DNAmodification efficiency was ensured by triplet analysis
of each tumor sample, including DNA quantification and constant positive and negative con-
trols. As negative controls, white matter obtained from 5 non-tumorous biopsies from patients,
aged between 40 and 50 years, were used.MGMT positive controls were used from tumor
material, analyzed by bisulfite-sequencing. Prior to pyrosequencing ofMGMT, the extracted
DNAmust be treated with bisulfite to guarantee restricted detection of methylated cytosine
[32,33]. This was conducted using the EZ DNAMethylation kit (Zymo Research, Irvine, CA)
according to the manufacturer’s protocol. From each patient 500 ng of genomic DNA were
submitted for bisulfite conversion. Consecutive PCR amplification was performed using primer
sequences of a predesigned quantitative assay (Qiagen, Valencia, CA). The product ID is indi-
cated in S1 Table. 25 μl of the PCR product were used for pyrosequencing conducted on an
automated PyroMark Q24 System (Qiagen, Valencia, CA), following the manufacturer’s
instructions. Required, system-specific reagents and supplements (PyroMark Q96 Tests, ID
972032) were obtained from Qiagen (Valencia, CA).
Resulting data were analyzed and quantified with the PyroMark Q24 Software 2.0. Each
tumor and control sample was analyzed in triplicates by individual PCR reactions using the
same bisulfite preparation as template.
Mutational analysis of the IDH1 (codon 132) and IDH2 (codon 172)
genes
Mutational screening for IDH1 was assessed with a mutation specific IDH1 antibody and by
quantitative pyrosequencing. Staining for IDH1 R132H was carried out on 4 μm tissue sec-
tions from formalin-fixed, paraffin-embedded tumor specimens using the IDH1 R132H
antibody (dianova GmbH, Germany). This antibody detects the heterozygous R132H point
mutation of the IDH1 gene, resulting in a substitution of arginine to histidine at position
132 of the amino acid sequence. For the immunohistochemical reactions, paraffin sections
were dried at 80°C for 15 min and stained with the primary IDH1 antibody with a dilution
of 1:10 on a Ventana BenchMark XT1 immunostainer (Ventana Medical Systems, Tucson,
AZ) following the Ventana staining procedure. Immunoreaction was scored positive when
tumor cells showed a strong cytoplasmatic and nuclear staining for IDH1 R132H. The
presence of mutations affecting IDH1 codon 132 and IDH2 codon 172 were additionally
assessed by pyrosequencing using the same reaction solutions, system and software as
described above. The corresponding sequencing primers are given on request. Each tumor
sample was analyzed in triplicates and each control sample in duplicates by individual PCR
reactions. Non-neoplastic surgical biopsies of the white matter, obtained from 5 patients
served as control.
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Mutational analysis of the BRAF gene (position V600)
BRAFmutations in codon 600 refer to a T> A transversion, resulting in an amino acid substi-
tution of valine to glutamic acid. Pyrosequencing for the detection of this specific point muta-
tion was performed as described above using a predesigned quantitative assay (BRAF Pyro Kit,
ID 970470) from Qiagen (Valencia, CA).
Statistical analyses
Pearson’s Chi-squared test with Yates’ continuity correction and Fisher’s exact tests were used
to determine the association of categorical variables. Statistical significance was defined as p-
value< 0.05. Analyses were conducted using R statistical software R, version 3.2.1 (The R
Foundation for Statistical Computing, The R Foundation for Statistical Computing; http://
www.R-project.org).
Results
Clinical, histological and immunohistochemical data
The tumor samples were obtained from 54 patients, including 34 gcGBM (20 males, 14 females,
mean age at operation 54,9 years, range: 12–77) and 20 PXA (9 males, 11 females, mean age at
operation: 46,6 years, range: 14–85) (Tables 1 and 2). Clinical data concerning the localization
was available from all PXA and 31 of 34 gcGBM. gcGBM were mainly located in the frontal
(11), temporal (8) and parietal (5) lobe. PXA showed a preferential localization in the temporal
(10), followed by the frontal (5) lobe (Tables 1 and 2).
Immunohistochemical analysis of all tumor samples was carried out for GFAP, MAP2, p53,
CD34 and Ki-67. All gcGBM showed histomorphological criteria including vascular prolifera-
tions and/or focal necrosis. Dense reticulin fiber networks were focally observed in 11 of 34
gcGBM (32.4%) (Table 1, Table 3). GFAP and MAP2 positivity was found in all gcGBM,
whereas nuclear p53 positivity could be demonstrated in 73.5% (Table 1, Table 3). CD34
expression was present in 9 out of 34 gcGBM (26.5%) (Table 1, Table 3) and Ki-67 indexes
were elevated in all of the gcGBM, defining an index range of 10 to 30%.
PXA showed reticulin fiber dispositions in 17 out of 20 tumors (85%) (Table 2, Table 3) and
were equally marked positively for GFAP and MAP2. p53 positivity was less frequent in PXA
(30% of cases), whereas CD34-expression was detected in 14 out of 20 PXA (70%) (Table 2,
Table 3). PXA were also positively marked for Ki-67, PXA (WHO grade II) showing a prolifer-
ation index below 5%. 14 out of 20 PXA fulfilled the criteria for anaplasia (5 or more mitoses
per 10 HPF) and were designated as PXA with anaplastic features. The proliferative activity
was up to 10% of the tumor cells. Focal necrosis in PXA was also designated as a hallmark of
anaplasia. There was no difference in localization preference between PXA and PXA-A
observed.
MGMT promoter methylation is much more frequent in gcGBM than in
PXA
We examined 20 PXA and 34 gcGBM by quantitative pyrosequencing forMGMT promoter
methylation status under standardized conditions as mentioned above. Three out of 20 PXA
(15%) including two PXA which was designed as PXA with anaplastic features (PXA-A),
showed a hypermethylation of theMGMT promoter whereas 14 out of 34 gcGBM were hyper-
methylated (Tables 1, 2 and 3), which corresponds to 41.2% (Fig 1A, Table 3). But statistical
analysis did not confirm relevant statistical significance between both tumor entities and their
methylation status (Pearson’s Chi-squared test with Yates’ continuity correction 2.88; p-value
MGMT,MGMT V600E and IDH1/2 in gcGBM and PXA
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0.09 and Fisher’s exact test p-value< 0.07, CI 95%, OR 0.26). Age and gender specific varia-
tions were not found in the groups.
IDH1 (R132) and IDH2 (R172) point mutations are absent in gcGBM and
PXA
PXA and gcGBM, were stained with a mutation specific antibody against the IDH1 residue
R132H on an automated immunostainer (Ventana Medical Systems). None of the PXA or the
gcGBM was marked positive. However, one PXA-A showed a focal, slight nuclear staining in
Table 1. gcGBM: Patients, histology, immunohistochemical andmolecular markers.
Age*/yr Sex Location Histology p53 Reticulin CD34 MGMT BRAF
1 77 F temporal lobe gcGBM + - + - -
2 50 M occipital lobe gcGBM + - - - -
3 74 M occipito-temporal gcGBM + + - - -
4 56 M temporo-mesial gcGBM - - + - -
5 55 M insula gcGBM - - - - -
6 62 F frontal lobe gcGBM + - + - -
7 59 F parieto-occipital gcGBM - - - + -
8 73 M post-central gcGBM + + + - -
9 52 F cerebellum gcGBM + - - - -
10 45 F not speciﬁed gcGBM + - - - -
11 47 M temporal lobe gcGBM + + + - -
12 74 M frontal lobe gcGBM - - - - -
13 73 M occipital lobe gcGBM + + + + -
14 71 F frontal lobe gcGBM + + + - -
15 66 F frontal lobe gcGBM + - - + -
16 57 M parietal lobe gcGBM + - - + -
17 42 M central gcGBM - - - + -
18 53 F falx cerebri gcGBM + + - - -
19 74 M frontal lobe gcGBM - - - - -
20 48 F frontal lobe gcGBM - - - + -
21 59 M temporal lobe gcGBM + - - + -
22 65 M not speciﬁed gcGBM + - - - -
23 61 M frontal lobe gcGBM - - - + -
24 69 F frontal lobe gcGBM + + + - -
25 49 F frontal lobe gcGBM + + - - -
26 45 M temporal lobe gcGBM + - - + -
27 12 M hippocampus gcGBM + + - - -
28 20 F occipital lobe gcGBM + - - + -
29 18 F not speciﬁed gcGBM + - + - -
30 28 M frontal lobe gcGBM - - - + -
31 66 F parieto-occipital gcGBM + - - - -
32 56 M parietal lobe gcGBM + - - + -
33 60 M temporal lobe gcGBM + + - + -
34 50 M frontal lobe gcGBM + + - + -
* age at timepoint of diagnosis
List of 34 cases diagnosed gcGBM, indicating age, gender and tumor location as well as the histological, immunohistochemical and molecular marker
proﬁle.
doi:10.1371/journal.pone.0156422.t001
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the tumor cells, but not a significant positivity. Additional pyrosequencing revealed no hetero-
zygous A to G point mutation in codon R132 of the IDH1 gene in any of the tested PXA or
gcGBM samples. IDH2mutations were analyzed by pyrosequencing and were also not detected
in any of the groups (data not shown).
BRAF (V600E) mutations are restricted to PXA
BRAF V600E mutations were equally determined by quantitative pyrosequencing, mentioning
that 14 PXA were designated PXA with anaplastic features (PXA-A). A conformation change
Table 2. PXA and PXA-A: Patients, histology, immunohistochemical andmolecular markers.
Case Age*/yr Sex Location Histology p53 Reticulin CD34 MGMT BRAF
1 61 F temporal lobe PXA-A - + + + -
2 33 F thalamus PXA-A - - - - -
3 15 F temporal lobe PXA - + + + +
4 59 M frontal lobe PXA + + + - +
5 15 F central PXA-A - + + - +
6 66 M temporal lobe PXA-A - - + - -
7 45 M cerebellum PXA-A - - - - -
8 52 F frontal lobe PXA-A - + + - -
9 52 F temporal lobe PXA-A + + + - +
10 52 M temporal lobe PXA-A - + + - -
11 54 M temporal lobe PXA-A + + + - +
12 14 F frontal lobe PXA - + + - +
13 85 M frontal lobe PXA + + - - -
14 52 M bifrontal PXA-A - + + - -
15 47 M pons PXA-A - + + - -
16 60 F temporal lobe PXA - + + - +
17 21 M temporal lobe PXA - + + - +
18 51 F temporal lobe PXA-A + + - - +
19 51 F parietal lobe PXA-A - + - - -
20 30 F temporal lobe PXA-A + + - + +
* age at timepoint of diagnosis
List of 20 cases diagnosed PXA, including 14 PXA-A. The distribution of age, gender, tumor location as well as histological, immunohistochemical and
molecular marker proﬁle are given case-wise.
doi:10.1371/journal.pone.0156422.t002
Table 3. Comparative marker distribution in gcGBM and PXA.
gcGBM PXA p-value*
MGMT 41% (n = 14/34) 15% (n = 3/20) 0,009
BRAF V600E 0% (n = 0/34) 50% (n = 10/20) < 0,001
CD34 27% (n = 9/34) 70% (n = 14/20) 0,005
Reticulin 32% (n = 11/34) 85% (n = 17/20) < 0,001
TP53 74% (n = 25/34) 30% (n = 6/20) 0,005
* p-values were calculated using Pearson’s Chi-squared test with Yates continuity correction
Beside the histochemical and immunohistochemical markers reticulin, p53 and CD34, MGMT promoter
methylation and in particular BRAF V600E mutation do represent helpful molecular markers to differentiate
PXA from gcGBMs.
doi:10.1371/journal.pone.0156422.t003
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in the BRAF V600E gene was found in 5 PXA and 5 PXA-A in total corresponding to 50%
(Tables 1, 2 and 3, Fig 1). In the gcGBM group none of the 34 samples were mutated, (Pear-
son’s Chi-squared test with Yates’ continuity correction 17.68; p-value< 0.001). Age and gen-
der specific mutation rates were detected in none of the groups.
Discussion
The differential diagnosis of PXA and gcGBM is mostly successfully answered by histochemical
and immunohistochemical stainings, lightening specific hallmarks of both tumor entities.
However, some cases remain uncertain due to their untypical histologic patterns and immuno-
histochemical marker reaction[8,34] and require additional diagnostic measures for appropri-
ate diagnosis and consecutive personalized treatment, as experienced in the case of a 51 years
old patient (compare case 19, Table 2, Fig 2). Our data indicated that in particular reticulin
fiber depositions and CD34 expression, which were routinely used in PXA and gcGBM histol-
ogy are robust diagnostic markers in PXA (Pearson’s Chi-squared test with Yates’ continuity
correction for CD34 8.06; p-value 0,005 and for reticulin 12,88; p-value< 0,001, compare
Table 3), but should be used with caution for differentiation purposes of both entities, as a
dense reticulin fiber network and CD34 expression were also detected in more than 25% of
gcGBM. In this context we hypothesized that genetic changes in theMGMT, IDH1/2 and
BRAF genes, which are currently considered to be most relevant for molecular diagnostics in
glial tumors[11], could represent a new diagnostic tool for the integration of “boarder-line
cases” based on their specific genetic fingerprints.
MGMT promoter hypermethylation was only found in 1 PXA and 2 PXA-A respectively. In
contrast, gcGBMMGMT promoter hypermethylation occurred in 14 out of 34 cases, indicating
prognostic and therapeutic implications and being suggestive for a prolonged survival as
already described in GBM withMGMT promoter hypermethylation by Krex at al[35]. Other
studies by Marucci & Morandi and Gömöri et al. analysed the frequency ofMGMT promoter
Fig 1. MGMT and BRAF V600 analysis in gcGBM and PXA. A Hypermethylation ofMGMT was detected in 2 PXA (10%) and 14 gcGBM (41,2%).B
5 PXA and 6 PXA-A (55%) reveal V600E mutations in the BRAF gene, while being absent in gcGBM.
doi:10.1371/journal.pone.0156422.g001
MGMT,MGMT V600E and IDH1/2 in gcGBM and PXA
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methylation in 11 PXA and 18 samples of primary and recurrent gliomas respectively. Marucci
& Morandi detectedMGMT promoter methylation in 2 PXA (WHO grade II), whereas none
in the anaplastic variant (WHO grade III)[36]. Interestingly in our study 2 of 3 PXA with
detected MGMT promoter methylation were anaplastic variants. Gömöri et al. reported pres-
ent MGMT promoter methylation in both of the included gcGBM independent from tumor
progression[37]. Our data emphasize thatMGMT promoter hypermethylation is a rare epige-
netic event in PXA and more typical for gcGBM. Although statistic analysis did not confirm
MGMT promoter methylation as valid differential diagnostic marker (Pearson’s Chi-squared
test with Yates’ continuity correction 2,88; p-value 0,009) for gcGBM and PXA, the finding of a
MGMT hypermethylation in a PXA should be interpreted with caution and automatically lead
to questioning and re-evaluation of the given diagnosis.
Using the DNA based pyrosequencing method we could confirm former studies that BRAF
V600E mutations are a typical molecular event in PXA[28,38–40]. In contrast, we were not
able to detect BRAF V600E mutations in any of the analyzed gcGBM demonstrating a statisti-
cally significant relevance of the BRAF V600E mutations in the diagnosis of PXA versus
gcGBM (p-value<0.001). A high frequency of BRAFmutations in PXA compared to a lower
frequency in gcGBM was already documented elsewhere. However, most of these studies
included smaller sample sizes of one or both tumor entities or a relevantly differing research
question [27,41,42]. To our knowledge this was the largest cohort of gcGBM and PXA, in
which the BRAF V600E status was determined and therefore represents currently the most sub-
stantiated results, going in line with the previously reported findings. Another aspect of com-
parative study analyses is the variation of results related to distinct methods applied. For
example the study of Dahiya et al. analyzed BRAF V600E mutations in pediatric and adult glio-
blastoma via immunohistochemistry using a BRAF V600E specific antibody. They could detect
in each cohort 3 cases that were BRAF V600E-immunoreactive, including 2 giant cell variants
in the adult group. Immunoreactivity was limited to the giant cells[41]. In our study we used a
molecular approach, based on DNA sequencing, thus difficult to compare. However, this study
is representative for the key issue of our study, questioning correct diagnosis of gcGBM if a
BRAFmutation is detected. According to our results and those of previous studies[42], we
emphasize that malignant astroglial tumors with histomorphological and immunohistochemi-
cal features of a giant cell glioblastoma, in which a BRAF V600E mutation is detected with a
mutation specific antibody or by DNA sequencing should be re-examined to definitely exclude
diagnosis of PXA. Another important issue is that in this study we did not analyzed the BRAF-
KIAA1549 fusion as it displays a separate rearrangement with a distinct pathophysiological
pathway, being predominantly found in pilocytic astrocytoma (PA). However, Antonelli et al.
reported the occurrence of a KIAA1549:BRAF fusion gene in 1 anaplastic PXA, while being
negative for a BRAF V600E mutation[43]. This finding indicates that the molecular profile of
PXA is not fully elucidated yet and needs further analysis in bigger cohorts.
While IDH1/2mutations occur in diffuse astrocytoma, oligodendroglial tumors and second-
ary glioblastoma they were absent in our PXA and gcGBM samples, which differentiates PXA
as well as gcGBM from diffuse astrocytoma. We could not identify IDH1mutations as a
Fig 2. “Borderline Case” demonstrating that MGMT and BRAF are helpful additional molecular markers to differentiate PXA
from gcGBM. A Tumor specimen of a 51-years old female patient, located in the right parietal region: T1-weighted, contrast-
enhanced MRI scan shows a well-circumscribed, vascularized and in-homogeneously contrasted tumor, suspicious for focal
necrosis. B HE staining displays a pleomorphic astroglial tumor with giant cells, elevated mitotic activity and palisading necrosis.C
Reticulin fiber dispositions are present around the vessel walls, whileD CD34 expression is limited to the vessels. E As the
proliferative index additionally accounts for 20% the tumor was initially classified as giant cell glioblastoma (WHO grade IV). F
Pyrogram indicating a significantMGMT hypermethylation and G BRAF V600Emutation. For that reason the tumor was finally
classified as PXA with anaplastic features (analogues to grade III).
doi:10.1371/journal.pone.0156422.g002
MGMT,MGMT V600E and IDH1/2 in gcGBM and PXA
PLOSONE | DOI:10.1371/journal.pone.0156422 June 2, 2016 10 / 14
significant distinguishing feature of PXA and gcGBM. Moreover, putative IDH1mutations,
which were detected with a mutation specific IDH1 antibody by immunohistochemistry, need
to be interpreted carefully as only tumor samples with intense immunoreactivity were mutated
within the pyrosequencing analysis.
Recently, a significant coincidence of positive BRAFmutation status and temporal tumor
localization, as well as an abundant formation of reticulin fibers in BRAF-mutated PXA was
found by Koelsche et al.[44]. Moreover, PXA with BRAFmutations are highly associated with
expression of the CD34-antigene[44]. In our study we could confirm a high incidence of BRAF
mutations in temporal located PXA (7 of 10; 70%, Fig 3). Interestingly, nearly all BRAF
mutated PXA, which were located in the temporal lobe, reveal also a dense reticulin fiber net-
work and expressed CD34, indicating that these PXA are distinct from the PXA in non-tempo-
ral located areas, which had a heterogeneous histochemical-, immunohistochmical- and BRAF-
profile (Fig 3). In the gcGBM group we did not detect any specific correlations between locali-
zation, histology, immunohistochemical and mutational results.
Conclusion
In this study we could approve the diagnostic efficiency of molecular genetic analysis in the dif-
ferentiation of gcGBM and PXA in the presence of atypical histological and immunohisto-
chemical appearance. Our data reveal that BRAF V600E mutations do represent a common
hallmark in PXA while being absent in gcGBM and therefore are a helpful molecular (diagnos-
tic) marker to differentiate PXA from gcGBM (p-value<0,001).MGMT promoter hyper-
methylation is highly related to gcGBM and rare in PXA and therefore a well-suited,
complementary diagnostic tool for the differentiation of PXA and gcGBM besides offering
Fig 3. Correlation of histological andmolecular markers in temporal and non-temporal located PXA.
BRAF V600Emutations were found in 70.0% of all PXA with temporal localization (n = 7). 6 of these patients
showed simultaneous reticulin and CD34 expression. Both PXA that harbored a methylation of theMGMT
promoter were located in the temporal lobe. A slightly higher incidence of reticulin fiber disposition and CD34
expression was found in temporal tumors.
doi:10.1371/journal.pone.0156422.g003
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additional implications for targeted therapies. Being aware of the clinical and therapeutic rele-
vance ofMGMT promoter methylation-associated higher efficiency of temozolomide or the
treatment opportunity with BRAF kinase inhibitors the investigation forMGMTmethylation
and BRAF V600E mutations should be implemented in the routine diagnostic of gcGBM and
PXA.
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